Ascelia Pharma AB (OSTO:ACE)

kr 9.65 -0.35 (-3.5%) Market Cap: 325.76 Mil Enterprise Value: 304.97 Mil PE Ratio: 0 PB Ratio: 4.38 GF Score: 21/100

Q4 2023 Ascelia Pharma AB Earnings Presentation Transcript
Feb 09, 2024
Q3 2023 Ascelia Pharma AB Earnings Call Transcript
Nov 09, 2023

kr2.88 (-3.52%)

Earnings
Q2 2023 Ascelia Pharma AB Earnings Call Transcript
Aug 18, 2023

kr3.27 (-5.49%)

Earnings
Q4 2022 Ascelia Pharma AB Earnings Call Transcript
Feb 10, 2023

kr14.18 (+0.57%)

Earnings
Q3 2022 Ascelia Pharma AB Earnings Call Transcript
Nov 04, 2022

kr22.7 (+10.73%)

Earnings
Q2 2022 Ascelia Pharma AB Earnings Call Transcript
Aug 18, 2022

kr22 (-2.65%)

Earnings
Q1 2022 Ascelia Pharma AB Earnings Call Transcript
May 11, 2022

kr20.25 (-3.11%)

Earnings
Q4 2021 Ascelia Pharma AB Earnings Call Transcript
Feb 10, 2022

kr25.8 (+1.57%)

Earnings
Q2 2021 Ascelia Pharma AB Earnings Call Transcript
Aug 19, 2021

kr32.05 (-4.75%)

Earnings

Q4 2022 Ascelia Pharma AB Earnings Call Transcript

Feb 10, 2023 / 09:00AM GMT

Release Date Price: kr14.18 (+0.57%)

Transcript

Magnus Corfitzen

Ascelia Pharma AB - CEO

Welcome, everyone, to the webcast for Ascelia Pharma's Q4 report in 2022. Since our last call -- we look forward to updating you on the progress. And since our last call, we have changed the setup of the conference call. So hopefully, we should have a better sound quality than what we had in our previous conference call.

Next slide, so we will be making certain forward-looking statements. So please pay attention to this.

Ascelia Pharma is dedicated to improve the life of people living with cancer by offering better treatment options. In particular, we focus on rare cancer conditions. Our business model is to identify, develop, and commercialize novel drugs that address unmet medical needs within orphan oncology.

We have two drugs in clinical development. Orviglance is in an ongoing Phase 3 clinical study that we hope to complete soon. It will be the only product targeting an addressable market of $500 million to $600 million annually. Oncoral is ready to start Phase 2 for the treatment of gastric cancer based on encouraging results in

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.